Enterprise Value

-6.695M

Cash

16.82M

Avg Qtr Burn

-6.20M

Short % of Float

1.64%

Insider Ownership

4.48%

Institutional Own.

11.18%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
WP1066 (p-STAT3 inhibitor) Details
Solid tumor/s, Cancer, Brain tumor, Glioblastoma

Phase 2

Data readout

Phase 2

Update

Annamycin Details
Solid tumor/s, Cancer, Lung Metastases, Soft tissue sarcoma, Sarcoma

Phase 1/2

Data readout

Annamycin + Ara-C Details
Acute myeloid leukemia, Cancer, Blood cancer

Phase 1/2

Update

WP1066 (p-STAT3 inhibitor) Details
Cancer, Brain tumor, Solid tumor/s, Glioma

Phase 1/2

Initiation

WP1220 Details
Cancer, T-cell lymphoma, Cutaneous T cell lymphoma, Blood cancer

Phase 1

Update